

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/041508

International filing date: 09 December 2004 (09.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/528,017  
Filing date: 09 December 2003 (09.12.2003)

Date of receipt at the International Bureau: 12 January 2005 (12.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*January 03, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/528,017**

**FILING DATE: *December 09, 2003***

**RELATED PCT APPLICATION NUMBER: *PCT/US04/41508***



Certified By

Jon W Dudas

Under Secretary  
of Commerce for Intellectual Property  
and Acting Director of the  
United States Patent and Trademark Office

16310 U.S. PTO  
120903

PTO/SB/16 (10-01)  
Approved for use through 10/31/2002. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# **PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

Express Mail Label Number: EL210260765US

03917 U.S. PTO  
60/528017

120903

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Zoltan		Kiss		Austin, MN	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHOD FOR IMPROVING INSULIN SENSITIVITY BY ADMINISTERING AN INHIBITOR OF ANTITRYPSIN					
CORRESPONDENCE ADDRESS					
Direct all correspondence to:					
<input checked="" type="checkbox"/> Customer Number		<div style="border: 1px solid black; padding: 2px;">25764</div>		<div style="border: 1px solid black; padding: 5px; text-align: center;">           Place Customer Number Bar Code Label here         </div>	
OR _____ Type Customer Number here					
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		31		<input type="checkbox"/> CD(s), Number	
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		5		<input type="checkbox"/> Other (specify)	
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees					
FILING FEE AMOUNT \$80.00					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 06-0029					
<input checked="" type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted,

SIGNATURE

*Sean Mahoney*

Date December 9, 2003

TYPED or PRINTED NAME

Sean B. Mahoney

REGISTRATION NO.

51,984(if appropriate)

Docket Number:

73684-289759

TELEPHONE

612.766.7000

## **USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

SEND TO: Mail Stop Provisional Patent Application, Commissioner for Patents, P. O. MAIL STOP 1450, ALEXANDRIA, VA 22313-1450.

PATENT APPLICATION

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Applicant:</b> ZOLTAN KISS	
<b>Serial No.:</b> To Be Assigned	
<b>Filed:</b> Herewith	
<b>For:</b> METHOD FOR IMPROVING INSULIN SENSITIVITY BY ADMINISTERING AN INHIBITOR OF ANTITRYPSIN	<b>Docket No.</b> 73684-289759

Mail Stop PROVISIONAL APPLICATION  
Director – U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450

Express Mail No. EL210260765US

December 9, 2003

**TRANSMITTAL LETTER**

Enclosed for filing are the following papers in connection with the above-identified provisional patent application.

1. Provisional Application for Patent Cover Sheet (PTO/SB/16 – 1 page) with Specification (31 pages) and Drawings of Figures 1-5 (5 pages);
2. Credit Card Payment Form, PTO-2038, for \$80.00 to cover the filing fee;
3. Postcard.

A self-addressed return postcard in accordance with M.P.E.P. Section 503 itemizing all of the above-referenced documents filed with the United States Patent and Trademark Office.

**Filing Date**

This application is filed pursuant to 35 U.S.C. 111(b) and 37 CFR 1.53(c), and is being filed with the necessary specification. Please place this application on file upon receipt with a filing date of **December 9, 2003**.

**Small Entity Status**

Applicant claims Small Entity under 37 CFR 1.27.

**Deposit Account**


In the event the amount submitted herewith is insufficient in any respect, the Commissioner is hereby authorized to charge the balance needed to our Deposit Account No. 06-0029 and is requested to notify us of the same.

Respectfully submitted,

Dated: December 9, 2003

ZOLTAN KISS

By:

  
Sean B. Mahoney, #51,984  
Customer No. 25764

METHOD FOR IMPROVING INSULIN SENSITIVITY BY ADMINISTERING AN INHIBITOR OF  
ANTITRYPSIN

Technical Field

The present invention relates to methods of delaying the onset or treating the progression of type 2 diabetes in subjects that have increased blood levels of an inflammation marker protein. In one embodiment, the method includes administering an inhibitor of  $\alpha_1$ -antitrypsin (AT) to the subject and co-administering an anti-diabetic medicament to the subject. Treatment regimens provided by the method may also be used to delay the onset or control type 2 diabetes.

Significant recent changes in human behavior and lifestyle as well as the human environment have resulted in the escalation of diabetes during the last decades. Diabetes is a disease characterized by elevated levels of blood plasma glucose, or hyperglycemia. Hyperglycemia, if uncontrolled, can lead to other complications, such as blindness, kidney disease, heart disease, stroke, nerve diseases, circulatory disorders, and impotence in males. Diabetes is a chronic disease with diverse pathologic manifestations, and is accompanied by lipid metabolism and cardiovascular disorders as well as glycometabolism disorders.

Diabetes already afflicts an estimated 6% of the adult population in Western society, and its worldwide frequency is projected to grow by 6% per annum, potentially reaching a total of 200-300 million cases in 2010 [Zimmet, P., Alberti, K.G.M. and Shaw, J., "Global and societal implications of the diabetes epidemic." *Nature* **414**, 782-787 (2001)]. The main forces driving this increasing incidence are sedentary lifestyle and a staggering increase in obesity.

Diabetes is a potentially very dangerous disease because it is associated with markedly increased incidence of coronary, cerebral, and peripheral artery disease. As a result, patients with diabetes have a much higher risk of myocardial infarction, stroke, limb amputation, renal failure, or blindness. Atherosclerotic cardiovascular disease is responsible for 80% of diabetic mortality and more than 75% of all hospitalizations for diabetic complications [Moller, D.E., "New drug targets for Type 2 diabetes and the metabolic syndrome." *Nature* **414**, 821-827(2001)]. Recent evidence indicate that hyperglycemia leads

to overproduction of superoxide accounting for vascular damage, which, in turn, underlies most diabetic complications [Brownlee, M., "Biochemistry and molecular cell biology of diabetic complications." *Nature* **414**, 813-820 (2001); Ho, E. and Bray, T.M., "Antioxidants, NFκB activation, and diabetogenesis." *Proc. Soc. Exp. Biol. Med.* **222**, 205-213 (1999)].

5 In Type 2 diabetes, or non-insulin-dependent diabetes mellitus (NIDDM), muscle, fat, and liver cells are resistant to the actions of insulin. Furthermore, compensatory mechanisms that are activated in β-cells to secrete more insulin to maintain blood glucose levels within a normal physiological range fail to function properly. Type 2 diabetes accounts for about 90% of all diabetes [Saltiel, A.R., "New perspectives into the molecular pathogenesis and  
10 treatment of Type 2 diabetes." *Cell* **104**, 517-529 (2001)]. Type 2 diabetics are often prescribed blood glucose-lowering sulfonylurea-based or -derived drugs, which are associated with the stimulation of insulin production in the pancreatic β-cells. Alternatively, patients suffering from Type 2 diabetes may also be prescribed biguanide-based or -derived drugs, which are associated with increasing a patient's sensitivity to insulin. Inhibitors of α-  
15 glucosidase, which decrease absorption of glucose from the intestine, may also be prescribed. Finally, thiazolidinediones, may be prescribed.

Despite large variations in carbohydrate intake with various meals, blood glucose normally remains in a narrow range between 4 and 7 mM in non-diabetic individuals. Such tight control is regulated by the balance among three major mechanisms, i.e. (i) glucose  
20 absorption from the intestine, (ii) glucose production by the liver, and (iii) uptake and metabolism of glucose by the peripheral tissues, mainly the skeletal muscle and fat tissue. In skeletal muscle and fat tissue, insulin increases the uptake of glucose, increases the conversion of glucose to glycogen, and increases conversion of glucose to fat (mainly triglycerides). In the liver, insulin inhibits the release of glucose from glycogen. Insulin is the  
25 only known hormone which can regulate all three mechanisms required to maintain the blood glucose level in the normal range [Saltiel, A.R. and Kahn, C.R., "Insulin signaling and the regulation of glucose and lipid metabolism." *Nature* **414**, 799-806 (2001)].

Diabetes mellitus is a heterogeneous group of disorders characterized by high blood glucose (sugar) levels. There are two main types of diabetes. Type 1, or insulin-dependent  
30 diabetes, results from a deficiency of insulin due to autoimmune destruction of the

insulin-producing pancreatic  $\beta$ -cell islets [Bell, G.I. and Polonsky, K.S., "Diabetes mellitus and genetically programmed defects in  $\beta$ -cell function." *Nature* **414**, 788-791 (2001); Mathis, D., Vence, L. and Benoist, C., " $\beta$ -cell death during progression to diabetes." *Nature* **414**, 792-798 (2001)]. People with Type 1 diabetes must take exogenous insulin for survival to prevent the development of ketoacidosis.

Recently, a lot of effort has been made to determine the factors that contribute to diabetes. It is clear that these factors include free fatty acids (FFAs), particularly the saturated species. In the liver, FFAs cause insulin resistance by inhibiting insulin suppression of glycogenolysis resulting in increased glucose output [Boden, G., Cheung, P., Stein, T.P., Kresge, K. and Mozzoli, M., "FFA cause hepatic insulin resistance by inhibiting suppression of glycogenolysis." *Am. J. Physiol. Endocrinol. Metab.* **283**, E-12-E19 (2001)]. In muscle, FFAs decrease insulin sensitivity by inhibiting phosphatidylinositol 3-kinase activity, a downstream effector of insulin action [Yu, C., Chen, Y., Cline, G.W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, M.F., Cushman, S.W., Cooney, G.J., Atcheson, B., White, M.F., Kraegen, E.W. and Shulman, G.I., "Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase in Muscle." *J. Biol. Chem.* **277**, 50230-50236 (2002)]. Finally, in the pancreas, saturated FFAs induce apoptotic death of  $\beta$ -cells [Maedler, K., Spinas, G.A., Dyntar, D., Moritz, W., Kaiser, N. and Donath, M.Y., "Distinct effects of saturated and monounsaturated fatty acids on  $\beta$ -cell turnover and function." *Diabetes* **50**, 69-76 (2001)].

Another risk factor for developing type 2 diabetes is inflammation, including subchronic inflammation, which is accompanied by the synthesis of liver-derived acute phase proteins such as C-reactive protein,  $\alpha_1$ -antitrypsin (AT), serum amyloid, haptoglobin, fibrinogen,  $\alpha_1$ -acid glycoprotein, and  $\alpha_1$ -antichymotrypsin. Of the currently recognized mediators of inflammation (tumor necrosis factor, interleukin-1, and interleukin-6) only interleukin-6 is capable of eliciting the full range of acute phase protein changes seen in inflammation. Of the inflammation markers, interleukin-6, along with C-reactive protein, has definitely been identified as a risk factor for developing type 2 diabetes [Pradhan, A.D., Manson, J.E., Rifai, N., Buring, J.E. and Ridker, P.M., "C-reactive protein, interleukin 6, and

risk of developing type 2 diabetes mellitus. *JAMA* **286**, 327-334 (2001)]. The mechanism by which inflammation modulates insulin sensitivity is presently not clear. However, it is clear that insulin is capable of down-regulating cytokine-stimulated expression of acute phase protein in liver cells [Thompson, D., Harrison, S.P., Evans, S.W. and Whicher, J.T. "Insulin modulation of acute-phase protein production in a human hepatoma cell line." *Cytokine* **3**, 619-626 (1991); Campos, S.P. and Baumann, H. "Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes." *Mol. Cell. Biol.* **12**, 1789-1797 (1992)].

Since interleukin-6 also regulates hepatic synthesis of AT, one would expect that increases in blood AT level, as part of the acute phase response, will also be indicative of risk for developing type 2 diabetes. Indeed, several laboratories consistently found that higher than normal blood concentrations of AT, along with other acute phase proteins, predict type 2 diabetes [Ganrot, P.O, Gydell, K. and Ekelund, H. "Serum concentration of  $\alpha_2$ -macroglobulin, haptoglobin and  $\alpha_1$ -antitrypsin in diabetes mellitus." *Acta Endocrinologica* **55**, 537-544 (1967); McMillan, D.E. "Increased levels of acute-phase serum proteins in diabetes." *Metabolism* **38**, 1042-1046 (1989); Schmidt, M.I., Duncan, B.B., Sharrett, A.R., Lindberg, G., Savage, P.J., Offenbacher, S., Azambuja, M.I., Tracy, R.P. and Heiss, G. "Markers of inflammation and prediction of diabetes mellitus in adults." *The Lancet* **353**, 1649-1652 (1999)]. However, it is not known whether the relationship between AT level and diabetes is causal or not.

AT belongs to the large family of serine protease inhibitors, or serpins, that act as irreversible suicide inhibitors of proteases [Janciauskiene, S. "Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles." *Biochim. Biophys. Acta* **1535**, 221-235 (2001)]. AT is a particularly effective inhibitor of elastase, but is also inhibits other proteases such as trypsin. AT deficiency, often caused by its oxidative damage in smokers, is causally related to emphysema due to the uncontrolled action of proteases in the lung. AT deficiency may be reversed by replacement therapy with purified AT [Wewers, M.D., Casolaro, M.A., Sellers, S.E., Swayze, S.C., McPhaul, K.M., Wittes, J.T. and Crystal, R.G. "Replacement therapy for  $\alpha_1$ -antitrypsin deficiency associated with emphysema." *N. Engl. J. Med.* **316**, 1055-1062 (1987)].



AT has several biological actions that may or may not relate to its ability to inhibit proteases. Thus, AT has been shown to both stimulate and inhibit proliferation of various cell types [Perraud, F., Besnard, F., Labourdette, G. and Sensenbrenner, M. "Proliferation of rat astrocytes, but not of oligodendrocytes, is stimulated in vitro by protease inhibitors." *Int. J. Devl. Neuroscience* **6**, 261-266 (1988); She, Q.-B., Mukherjee, J.J., Crilly, K.S. and Kiss, Z. "α<sub>1</sub>-Antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines." *FEBS Lett.* **473**, 33-36 (2000); Dabbagh, K., Laurent, G.J., Shock, A., Leoni, P., Papakrivopoulou, J. and Chambers, R.C. "Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signaling pathways." *J. Cell. Physiol.* **186**, 73-81 (2001); Graziadei, I., Gaggli, S., Kaserbacher, R., Braunsteiner, H. and Vogel, W. "The acute phase protein α<sub>1</sub>-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferring iron uptake. *Blood* **83**, 260-268 (1994)]. AT also was shown to block the release of transforming growth factor-α from MCF-7 human breast cancer cells resulting in decreased growth [Yavelow, J., Tuccillo, A., Kadner, S.S., Katz, J. and Finlay, T.H. "α<sub>1</sub>-Antitrypsin blocks the release of transforming growth factor-α from MCF-7 human breast cancer cells." *J. Clin. Endocrinol. Metab.* **82**, 745-752 (1997)]. In rats, administration of AT promoted hepatic fibrosis [Ozeki, T., Imanishi, K., Ueda, H., Uchiyama, T., Funakoshi, K., Suzuki, K., Ohuchi, K., Kan, M. and Satoh, T. "α<sub>1</sub>-Antitrypsin and hepatic fibrosis." *Br. J. Exp. Path.* **70**, 143-152 (1989)]. Finally, in monocytes, AT was found to modulate iron metabolism [Graziadei, I., Weiss, G., Egger, C., Niederwieser, D., Patsch, J.R. and Vogel, W. "Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein α<sub>1</sub>-antitrypsin." *Exp. Hematol.* **26**, 1053-1060 (1998)]. None of these effects are related to the effects of AT on insulin sensitivity as revealed in this application.

Several studies demonstrated that the activity of AT can be inhibited by gemfibrozil (GF) [Janciauskiene, S. and Eriksson, S. "An interaction between Gemfibrozil and alpha<sub>1</sub>-antitrypsin." *J. Internal Med.* **236**, 357-360 (1994)], hydrophobic bile acids [Janciauskiene, S. and Eriksson, S. "The interaction of hydrophobic bile acids with the α<sub>1</sub>-proteinase inhibitor."

*FEBS Lett.* **343**, 141-145 (1994)], and cholesterol [Janciauskiene, S. and Eriksson, S. "In vitro complex formation between cholesterol and  $\alpha_1$ -proteinase inhibitor." *FEBS Lett.* **316**, 269-272 (1993)]. GF has been used in human therapy to decrease plasma triglyceride levels and enhance high-density lipoprotein cholesterol (good cholesterol) levels in order to prevent coronary heart disease [Yuan, J., Tsai, M.Y. and Hunninghake, D.B. "Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy." *Atherosclerosis* **110**, 1-11 (1994); Schaefer, E.J., Lamon-Fava, S., Cole, T., Sprecher, D.L., Cilla, D.D., Balagtas, C.C., Rowan, J.P. and Black, D.M. "Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels." *Atherosclerosis* **127**, 113-122 (1996); Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., Faas, F.H., Linares, E., Schaefer, E.J., Schectman, G., Wilt, T.J., and Wittes, J. "Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol." *N. Engl. J. Med.* **341**, 410-418 (1999)]. In none of these studies did GF exert any significant side effects, which makes it an attractive candidate to inhibit the activity of excess AT that reduces insulin sensitivity.

Data in the literature provide guidance with respect to the amount of GF that will inhibit the activity of excess AT without compromising the basic physiological function of the remaining active AT [Janciauskiene, S. and Eriksson, S. "An interaction between Gemfibrozil and  $\alpha_1$ -antitrypsin." *J. Internal Med.* **236**, 357-360 (1994)].

### Summary of the Invention

In one embodiment, the present invention provides a method of treating or delaying the progression or onset of diabetes in subjects that exhibit above-normal blood levels of inflammation marker protein by administering an inhibitor of  $\alpha_1$ -antitrypsin (AT). Inflammation marker proteins include  $\alpha_1$ -antitrypsin (AT), interleukin-6, and C-reactive protein. Suitable inhibitors of AT include gemfibrozil (GF) and active derivatives thereof, and lithocholic acid (LCA) and active derivatives thereof. The method may include further

co-administering an anti-diabetic medicament. The anti-diabetic medicament may be insulin, an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or combinations of these. The method may include further administering an anti-inflammatory agent. The subject for these methods may be a human or other mammal.

5 In another embodiment, the present invention provides a method of enhancing or restoring the sensitivity of mammals to the metabolic actions of insulin in subjects who exhibit above-normal blood levels of inflammation marker protein by administering an inhibitor of  $\alpha_1$ -antitrypsin (AT) sufficient to enhance or restore the sensitivity of the subject to the metabolic actions of insulin. The method may include further co-administering an anti-  
10 diabetic medicament. The anti-diabetic medicament may be insulin, an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or combinations of these. The method may include further administering an anti-inflammatory agent.

In still another embodiment, the present invention provides a method of enhancing or restoring the sensitivity of a diabetic human to the metabolic actions of insulin by  
15 administering an inhibitor of  $\alpha_1$ -antitrypsin (AT). The method may include further co-administering an anti-diabetic medicament. The anti-diabetic medicament may be insulin, an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or combinations of these. The method may include further administering an anti-inflammatory agent.

20 In another embodiment, the present invention provides a treatment regimen of delaying the onset of diabetes in subjects who exhibit increased blood levels of inflammation marker protein by periodically administering an inhibitor of  $\alpha_1$ -antitrypsin (AT). The treatment regimen may include further co-administering an anti-diabetic medicament. The anti-diabetic medicament may be insulin, an insulin secretagogue, a biguanide, an inhibitor  
25 of  $\alpha$ -glucosidase, a thiazolidinedione, or combinations of these. The method may include further administering an anti-inflammatory agent.

The present invention also provides a treatment regimen for treating the progression of diabetes in subjects who exhibit increased blood levels of inflammation marker protein by administering an inhibitor of  $\alpha_1$ -antitrypsin (AT) as needed. The treatment regimen may

include further co-administering an anti-diabetic medicament. The anti-diabetic medicament may be insulin, an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or combinations of these. The method may include further administering an anti-inflammatory agent.

5        The following findings indicate that the methods and regimens of the invention maybe therapeutically effective: (i) in humans, there is a correlation between increased synthesis of AT and decreased insulin sensitivity, (ii) in glucose tolerance tests performed using an appropriate mouse model, administration of AT decreases the effects of insulin on glucose metabolism, and (iii) administration of GF *in vitro* inhibits the activity of AT and  
10        reduces AT's inhibitory effect on insulin-stimulated glucose metabolism.

#### Brief Description of the Drawings

**Fig. 1** shows a gel picture which indicates that purified AT, used for the experiments 2-5, does not contain visible amounts of contaminating proteins as determined by Coomassie  
15        blue staining. Lane 2 represents the starting material (human placental alkaline phosphatase from Sigma & Aldrich, Inc.); lanes 3 and 4 represent the presence of proteins after various purification steps; and lane 5 represents the final purified AT preparation as indicated by the arrow. Lane 1 contains molecular mass standards of 97 kDa (top), 66 kDa, 45 kDa, 31 kDa, and 22 kDa (bottom), in that order.

20        **Fig. 2** demonstrates that in fasting C57/Black female mice, (i) intraperitoneal administration of 3 g/kg glucose elevated the blood glucose level about 1.6 to 2.2-fold during the subsequent 3 hours period, (ii) insulin initially strongly inhibited the rise in blood glucose level, and that (iii) intraperitoneal administration of commercial AT (1.5 mg/mice)

administered 24 hours prior to administration of insulin blocked the action of insulin. The insert shows that AT alone had no significant effect on the blood glucose level.

5 **Fig. 3** demonstrates that in differentiated rat L6 muscle cells, insulin (▲) exerted more than two-fold stimulatory effects on the uptake of D-[<sup>14</sup>C]glucose (A) as well as the synthesis of [<sup>14</sup>C]glycogen (B) as compared to untreated cells (●), and that 0.4 mg/ml of purified AT (■) inhibited both insulin effects after incubations for 2 hrs or 6 hours, but not after 30 min incubation.

10 **Fig. 4** indicates the concentration-dependent inhibitory effects of AT (0-400 µg/ml) on insulin-stimulated (▲) cellular uptake of D-[<sup>14</sup>C]glucose (A) as well as synthesis of [<sup>14</sup>C]glycogen (B) and [<sup>14</sup>C]total lipid (C) from radiolabeled glucose in differentiated L6 cells. AT in the absence of insulin (●), had practically no effect.

15 **Fig. 5** demonstrates that in differentiated L6 cells, both GF and lithocholic acid (LCA) were capable of preventing the strong inhibitory effect of AT on insulin(Ins)-stimulated glycogen synthesis. Neither GF nor LCA had a significant effect in the absence of AT.

#### Detailed Description of the Invention

20 It has been found that AT synthesis and secretion is enhanced during inflammation, chronic and even sub-chronic inflammation as well as increased expression of AT are risk factors for type 2 diabetes, and that administration of AT to mice was able to completely block the insulin action on blood glucose level. Therefore, an appropriate level of inhibition

of AT may be effective to reverse reduction in insulin sensitivity and thereby decrease the chances of developing type 2 diabetes in a significant segment of population.

### **Treating or Delaying the Progression or Onset of Diabetes**

5 In one embodiment, the present invention provides a method of treating or delaying the progression or onset of diabetes in a mammal by identifying a mammal with above-normal blood levels of AT, interleukin-6, or C-reactive protein (collectively referred to as “inflammation marker proteins”), and administering to the mammal a therapeutically effective amount of inhibitor of  $\alpha_1$ -antitrypsin (AT).

10 A “therapeutically effective amount” of inhibitor of AT is targeted at attaining or maintaining a level of AT in the mammal’s blood that is within the normal range for that mammal. The range of normal AT level for humans is about 1.3 mg AT / mL blood. A therapeutically effective amount of inhibitor of AT may be effective in increasing the sensitivity of the mammal to the metabolic actions of insulin. A therapeutically effective amount of inhibitor of AT may be effective to inhibit the activity of excess AT without  
15 compromising the basic physiological function of the remaining active AT.

Since development of insulin insensitivity and type 2 diabetes are multi-factorial, there is a need for patient selection based on the blood levels of inflammation marker protein before administration of an AT inhibitor may be recommended. If determination of blood levels of inflammation marker protein, repeatedly indicate chronic or sub-chronic  
20 inflammation, then administration of AT inhibitor is expected to improve insulin sensitivity in these patients.

Any of the tests to determine blood levels of AT, interleukin-6 and C-reactive protein are readily performed by technicians trained in the art using commercially available kits and reagents. For example, the level of AT in the blood of a subject can be accurately determined  
25 by radial immunodiffusion of a sample of the subject’s blood using a kit from Behring Diagnostics (Mannheim, Germany). If the level of AT is found to be greater than the normal level of AT in the blood, which is about 1.3 mg AT per mL blood in humans, then administration of AT inhibitor is expected to improve insulin sensitivity.

The phrase “inhibitor of  $\alpha_1$ -antitrypsin” denotes an agent that inhibits the activity of AT. It is not intended to refer to an agent that does not inhibit the activity of AT such as an agent that inhibits cellular synthesis of AT.

Of the known inhibitors of AT, gemfibrozil (GF) has been the most studied. It is commercially available from Sigma-Aldrich, Inc. (St. Louis, MO). GF is used in humans to enhance the blood level of high density lipoprotein cholesterol and to decrease triglyceride level. Most regimens use 600-1200 mg GF once daily in an oral administration [Yuan, J., Tsai, M.Y. and Hunninghake, D.B. “Changes in composition and distribution of LDL subspecies in hypertriglyceridemic and hypercholesterolemic patients during gemfibrozil therapy.” *Atherosclerosis* **110**, 1-11 (1994); Schaefer, E.J., Lamon-Fava, S., Cole, T., Sprecher, D.L., Cilla, D.D., Balagtas, C.C., Rowan, J.P. and Black, D.M. “Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.” *Atherosclerosis* **127**, 113-122 (1996); Rubins, H.B., Robins, S.J., Collins, D., Fye, C.L., Anderson, J.W., Elam, M.B., Faas, F.H., Linares, E., Schaefer, E.J., Schectman, G., Wilt, T.J., and Wittes, J. “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.” *N. Engl. J. Med.* **341**, 410-418 (1999)]. These doses did not cause significant side effects. Thus, in subjects with high blood AT levels, daily administration of 600-1200 mg of GF appears to be safe.

The amount of GF required to be therapeutically effective can be measured in various ways. It has been shown that daily oral administration of GF at the 600 mg level inhibited AT activity by 30-60% [Janciauskiene, S. and Eriksson, S. “An interaction between Gemfibrozil and alpha<sub>1</sub>-antitrypsin.” *J. Internal Med.* **236**, 357-360 (1994)]. This observation provides a benchmark from which to calculate the amount of GF which needs to be administered to restore AT activity to the normal level. By way of example only, if the blood AT level is 30% higher than normal, then daily administration of about 300-600 mg of GF is expected to be sufficient to normalize AT activity and to significantly decrease the risk for type 2 diabetes. However, if AT activity is twice of the normal level, then 1,000-1,500 mg of GF per day may be initially needed to normalize the level of AT in the blood. Furthermore,

by monitoring the level of AT in a subject's blood, the amount of GF administered may be varied to maintain a near normal blood level of AT.

Active derivatives of GF, lithocholic acid (LCA), and active derivatives of LCA may also be used as an AT inhibitor. The inhibitors of AT may be administered in various ways including orally, intravascularly, intraperitoneally, subcutaneously, intramuscularly, intranasally, or topically, for example.

The method may further include the step of co-administering to the mammal an anti-diabetic medicament. The anti-diabetic medicament may include insulin, an insulin secretagogue, a biguanide, a sulfonylurea, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, human placental alkaline phosphatase, or a combination of these. These medicaments are known treatments of diabetes and may be administered orally or by any other suitable method. The term "co-administering" indicates that the anti-diabetic medicament and inhibitor of AT are administered as part of a planned course of treatment for treating or delaying the progression or onset of diabetes.

The method may also further include the step of administering to the mammal an anti-inflammatory agent. These agents are known in the art and may include non-steroidal anti-inflammatory drugs ("NSAIDs"), such as cyclooxygenase-2 inhibitors. Compounds that are cyclooxygenase-2 inhibitors and methods for the preparation of these compounds have been reported in the art. Representative compounds that are commercially available include rofecoxib (4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone), marketed under the trade name VIOXX (Merck & Co., Inc., Whitehouse Station, New Jersey), celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]), marketed under the trade name CELEBREX (G.D. Searle & Co., Chicago, Illinois), and valdecoxib (4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide), marketed under the trade name BEXTRA ((G.D. Searle & Co.). Other suitable anti-inflammatory agents include acetylsalicylic acid, ibuprofen, or active derivatives of these.

Administration of an anti-inflammatory agents may alter the amount of AT in the mammal. Therefore, if multiple administrations are given, the therapeutically effective amount of AT inhibitor may change to reflect the amount of AT in the mammal at the time the AT inhibitor is administered.



The method may be used to treat mammals that have been diagnosed as diabetic. It may also be used to delay the onset of diabetes in those mammals that are insensitive to the effects of insulin, but have not been diagnosed with diabetes. The method may be effective to reduce or maintain a human's blood glucose level to below about 10 mM, and preferably in the normal range of 4 mM to about 6 mM.

The method may also be used to prevent a mammal with type 2 diabetes from progressing into type 1 diabetes. If a mammal becomes less sensitive to insulin due to type 2 diabetes, the  $\beta$ -cell islets initially produce and release more insulin to compensate for decreased insulin sensitivity. After continual increased production of insulin, the insulin secretion system will break down, and the mammal will develop type 1 diabetes. By restoring the sensitivity of the mammal to insulin, the  $\beta$ -cell islets will produce normal amounts of insulin and are thus less likely to cease insulin production.

#### **Methods of Enhancing or Restoring Sensitivity to Insulin**

In another embodiment, the present invention provides a method of enhancing or restoring the sensitivity of a mammal to the metabolic actions of insulin. The method includes the steps of identifying a mammal with an above-normal level of inflammation marker protein, and administering an inhibitor of AT sufficient to enhance or restore the sensitivity of the mammal to the metabolic actions of insulin.

The method of selecting the mammals with above-normal blood levels of inflammation marker protein may be done in the manner described above. Additionally, the AT inhibitor may be gemfibrozil or an active derivative thereof, or lithocholic acid or an active derivative thereof, as described above. The AT inhibitor may be administered in the manner described above.

The method may further include the step of co-administering an anti-diabetic medicament to the subject. The anti-diabetic medicaments may include the agents described above. The method may also further include the step of administering to the mammal an anti-inflammatory agent. The anti-inflammatory agents are described above.

The method may be effective to reduce a human's blood glucose level to below about 10 mM, and preferably in the normal range of 4 mM to about 6 mM. The method may be

used in mammals that are diabetic, or in mammals that have lower than normal sensitivity to insulin but have not been diagnosed diabetic.

In another embodiment, the invention provides a method of enhancing or restoring the sensitivity of a diabetic human to the metabolic actions of insulin. The method includes the steps of identifying a diabetic human with an above-normal level of inflammation marker protein, and administering a therapeutically effective amount of an inhibitor of AT sufficient to enhance or restore the sensitivity of the diabetic human to the metabolic actions of insulin.

A “therapeutically effective amount” of inhibitor of AT is targeted at attaining or maintaining a level of AT in the mammal’s blood that is within the normal range for that mammal. The range of normal AT level for humans is about 1.3 mg AT / mL blood. A therapeutically effective amount of inhibitor of AT may be effective in increasing the sensitivity of the mammal to the metabolic actions of insulin. A therapeutically effective amount of inhibitor of AT may be effective to inhibit the activity of excess AT without compromising the basic physiological function of the remaining active AT.

The method may further include the step of co-administering an anti-diabetic medicament to the subject. The anti-diabetic medicaments may include the agents described above. The method may also further include the step of administering to the mammal an anti-inflammatory agent. The anti-inflammatory agents are described above.

The method may be effective to reduce the human’s blood glucose level to below about 10 mM, and preferably in the normal range of 4 mM to about 6 mM.

#### **Treatment Regimen of Delaying Onset of Diabetes**

In another embodiment, the present invention provides a treatment regimen for delaying the onset of diabetes in a mammal. The treatment regimen includes the steps of identifying a mammal with an above-normal level of an inflammation marker protein, and periodically administering to the mammal an inhibitor of AT.

A “therapeutically effective amount” of inhibitor of AT is targeted at attaining or maintaining a level of AT in the mammal’s blood that is within the normal range for that mammal. The range of normal AT level for humans is about 1.3 mg AT / mL blood. A therapeutically effective amount of inhibitor of AT may be effective in increasing the sensitivity of the mammal to the metabolic actions of insulin. A therapeutically effective

amount of inhibitor of AT may be effective to inhibit the activity of excess AT without compromising the basic physiological function of the remaining active AT.

The term “periodically” refers to repeated administration of AT inhibitor targeted to restoring or maintaining a normal about of AT in the mammal’s blood. In this embodiment, the periods do not have to be uniform. The therapeutically effective amount of AT inhibitor may be different at each administration depending upon the amount of AT or other inflammation marker protein present in the mammal.

The method may further include the step of co-administering an anti-diabetic medicament to the subject. The anti-diabetic medicaments may include the agents described above. The method may also further include the step of administering to the mammal an anti-inflammatory agent. The anti-inflammatory agents are described above.

#### **Treatment Regimen of Treating the Progression of Diabetes**

The invention provides a treatment regimen for treating the progression of diabetes in a mammal. The treatment regimen includes the steps of identifying a diabetic mammal with above-normal blood levels of inflammation marker protein, and administering an AT inhibitor as needed.

A “therapeutically effective amount” of inhibitor of AT is targeted at attaining or maintaining a level of AT in the mammal’s blood that is within the normal range for that mammal. The range of normal AT level for humans is about 1.3 mg AT / mL blood. A therapeutically effective amount of inhibitor of AT may be effective in increasing the sensitivity of the mammal to the metabolic actions of insulin. A therapeutically effective amount of inhibitor of AT may be effective to inhibit the activity of excess AT without compromising the basic physiological function of the remaining active AT.

The term “as needed” indicates that the therapeutically effective amount of AT inhibitor may be different at each administration depending upon the amount of AT or other inflammation marker protein present in the mammal.

The method may further include the step of co-administering an anti-diabetic medicament to the subject. The anti-diabetic medicaments may include the agents described above. The method may also further include the step of administering to the mammal an anti-inflammatory agent. The anti-inflammatory agents are described above.

The method may further include the step of monitoring the level of AT in the mammal's blood. If the level of AT is closer to an amount of AT that is normal for that mammal than when the mammal began the regimen, then the amount of AT inhibitor may be reduced to reflect the amount of AT in the mammal's blood.

5

### Examples

In a first set of experiments performed using an appropriate mouse model, the desensitizing effect of  $\alpha_1$ -antitrypsin (AT) on insulin-induced reduction of blood glucose levels was determined by classical glucose tolerance tests. In a second set of experiments, the desensitizing effect of AT on insulin-stimulated glucose metabolism in differentiated rat L6 muscle cells was confirmed. In a third set of experiments, two inhibitors of AT, gemfibrozil (GF) and lithocholic acid (LCA), were shown to prevent the desensitizing effect of AT on insulin-stimulated glycogen synthesis in differentiated L6 cells.

#### 15 *Example 1. Purification of AT.*

A partially purified human placental alkaline phosphatase preparation (PALP) was bought from Sigma-Aldrich, Inc. AT is the major contaminant of the commercially obtained PALP. The PALP was first purified by successive concanavalin A-Sepharose and Q-Sepharose chromatography as described Chang et al. [Chang, T.-C., Huang, S.-M., Huang, T.-M. and Chang, G.-G., "Human placenta alkaline phosphatase: An improved purification procedure and kinetic studies." *Eur. J. Biochem.* **209**, 241-247 (1992)]. The Q-Sepharose fraction, which still contained placental alkaline phosphatase in addition to AT, was further purified to homogeneity by *t*-butyl HIC chromatography [Chang, T.-C., Huang, S.-M., Huang, T.-M. and Chang, G.-G., "Human placenta alkaline phosphatase: An improved purification procedure and kinetic studies." *Eur. J. Biochem.* **209**, 241-247 (1992)]. The 5 ml bed volume *t*-butyl HIC cartridge was connected to a Pharmacia FPLC system and the fractions containing AT were pooled. The purity was confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) using Coomassie blue stain. The purified protein was identified as AT by sequence analysis. The sequence analysis was performed independently by the Mayo Clinic Protein Core Facility (Rochester, MN, USA). The protein

Method for Improving Insulin Sensitivity  
by Administering an Inhibitor of Antitrypsin

concentration was determined by the Lowry assay, using bovine serum albumin as standard, with a protein assay kit from Sigma-Aldrich, Inc. according to the instructions. This purification procedure has been previously published [She, Q.-B., Mukherjee, J.J., Crilly, K.S. and Kiss, Z. "α<sub>1</sub>-Antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines." *FEBS Lett.* **473**, 33-36 (2000)].

**Fig. 1** shows a picture of a stained gel. The gel includes partially purified Sigma placental alkaline phosphatase preparation (shown in lane 2), purified by successive Concanavalin A-Sepharose (lane 3), Q-Sepharose (lane 4), and *t*-butyl HIC chromatography using 2 M-0 M ammonium sulfate gradient (lane 5). Lane 1 contains molecular mass standards of 97 kDa (top), 66 kDa, 45 kDa, 31 kDa, and 22 kDa (bottom) in that order. Fig. 1 demonstrates that while the Sigma preparation contains 3 major proteins (one of them is AT as indicated by the arrow, while a ~66 kDa band represents placental alkaline phosphatase) and several minor proteins, the purified preparation contains only AT. Identification of the AT band by sequence analysis was performed by the Mayo Clinic Protein Core Facility (Rochester, MN, USA).

*Example 2 - Determination of blood glucose levels in C57/Black female mice in glucose tolerance tests.*

C57/Black female mice, weighing 22-23 g were fasted for 16 hours. Four animals were used for each of three treatment groups. The first treatment group received intraperitoneal injections of 1500 µg purified AT, i.e., AT purified by the procedure of Example 1. Exactly 23 hours and 45 minutes after the AT was administered to the first treatment group, the animals in the first and second treatment group received 0.5 I.U. of insulin. Exactly 15 minutes after the insulin was administered (or 24 hours after the AT was administered to the first treatment group), glucose (3 g/kg) was injected intraperitoneally into the first, second and third treatment groups. Blood samples were taken from the eyes (canthus), and glucose concentrations in whole blood samples were immediately measured with the fast Glucose C test (Wako Chemicals USA Inc., Richmond, Virginia, USA). The data presented are the mean ± S.D. of four determinations, one with each animal. The

experiment was repeated once using commercial AT (Sigma-Aldrich, Inc.) with similar results.

The results, shown in Fig. 2, demonstrate that in fasting mice, (i) intraperitoneal administration of 3 g/kg glucose elevated the blood glucose level about 1.6 to 2.2-fold during the subsequent 3 hours period, (ii) insulin initially strongly inhibited the rise in blood glucose level, and that (iii) prior (24 hours) intraperitoneal administration of purified AT (1.5 mg/mice) blocked the action of insulin. Data presented in the insert shows that administration of AT alone had no significant effect on the blood glucose level.

#### Examples 3-5 – Effects of AT on glucose uptake and metabolism in differentiated rat L6 muscle cells.

Rat L6 skeletal muscle cells were obtained from the American Type Culture Collection, Rockville, MD. L6 cell monolayers were induced to differentiate in Minimal Essential Medium (MEM) containing 2% (v/v) fetal bovine serum (FBS) and 1% (v/v) antibiotic/antimycotic solution. The cells were fed fresh medium every 48 hours. Myoblast differentiation, which occurred by about the 7-9<sup>th</sup> day, was monitored by phase contrast microscopy. Differentiated L6 cells are widely used models for studying glucose metabolism in the skeletal muscle. The present study was focused on these cells, because skeletal muscle accounts for about 70-80% of total blood glucose metabolism in the human body.

To examine cellular glucose uptake and metabolism, differentiated (attached) cells in 12-well plates were incubated at 37°C in a CO<sub>2</sub> incubator (95% air: 5% CO<sub>2</sub>) with D-[<sup>14</sup>C]glucose (1μCi/mL) in 2% FBS-containing medium containing 5.5 mM unlabeled glucose for 0.5-6 hours as indicated at the corresponding Figures. At the termination of incubation, the medium was removed. An aliquot of the medium was taken to determine the loss of [<sup>14</sup>C]glucose from the medium which corresponds to its uptake by cells. Cells were washed twice with 3 ml medium to remove traces of medium containing unincorporated radioactivity. Ice-cold 99.8% methanol/0.2% water (v/v) mixture (1 ml) was then added to the monolayers and cells were extracted for 2 hours at -20°C. This resulted in the precipitation of glycogen and the solubilization of cellular free glucose and lipids. The methanol phase (1 ml) and a following 1 ml methanol wash were added to 2 ml chloroform followed by the addition of 3 ml water. Of the resulting two phases (separation was

facilitated by brief centrifugation), the lower phase contained the total radiolabeled lipids, while the upper phase contained [ $^{14}\text{C}$ ]glucose.

Aliquots of the upper and lower phases were taken to scintillation vials to determine the amounts of radiolabeled glucose and total lipids, respectively, by liquid scintillation counting. Precipitated [ $^{14}\text{C}$ ]glycogen was suspended in 0.75 ml of 1 M NaOH and transferred to scintillation vial. This procedure was repeated with another 0.75 ml aliquot of NaOH. To neutralize the suspension, 10 mM HCl (approximately 150  $\mu\text{l}$ ) was then added to the vials, followed by the addition of 8.5 ml Ecolume (scintillation fluid). While the 1 M NaOH suspension contained some particulate material (mostly protein which was not labeled with radiolabeled glucose), no precipitate remained in the suspension after addition of Ecolume. This procedure resulted in quantitative removal of precipitated glycogen. No additional radioactivity could be removed from the well by neutralized 30% KOH.

In some experiments, a published procedure [Huang, D., Cheung, A.T., Parsons, J.T. and Bryer-Ash, M. "Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes." *J. Biol. Chem.* **277**, 18151-18160, (2002)] was used to determine glucose incorporation into glycogen in a method similar to the one described above. After incubations with [ $^{14}\text{C}$ ] glucose, cells were solubilized with 20% KOH for 2 hours. Lysates were extracted with 8% tricarboxylic acid, neutralized with 2.0 M HCl, then boiled for 5 min. The total glycogen was precipitated by the addition of 80% ethanol (final concentration) for 2 hours at  $-20^{\circ}\text{C}$  followed by centrifugation at  $1100 \times g$  for 10 min. This step was repeated.

After the pellets had been re-dissolved in distilled water, the samples were precipitated again using the same method described above, and yielded essentially the same results. In subsequent experiments the initial methanol precipitation method described above was used because it allowed for analysis of cellular glucose, glycogen and lipids from the same sample.

*Example 3 – Time-dependent effects of AT on insulin-stimulated glucose uptake and glycogen synthesis in differentiated L6 cells.*

Three groups of differentiated L6 cells, incubated in 12-well plates in 2% FBS-containing medium, were treated as follows. A first control group (●) was untreated. A second group (▲) was treated with 500 nM insulin for 30 min. A third group (■) was treated first with 0.4 mg/ml of AT followed by an addition of 500 nM insulin for 30 min. Following the addition of D-[<sup>14</sup>C]glucose, each group was incubated in the continuous presence of insulin and AT, as described above, for 0.5-6 hours.

For each group, the amounts of cellular radiolabeled glucose (Fig. 3A) and glycogen (Fig. 3B) were determined by liquid scintillation counting. The data are the mean ± S.D. of three independent incubations in one experiment (the experiment was repeated once with similar results). Compared to the control group (●), the cellular levels of both free [<sup>14</sup>C]glucose (Fig. 3A) and [<sup>14</sup>C]glycogen (Fig. 3B) were approximately doubled in the presence of insulin after incubations for 2-6 hours (▲). The addition of 0.4 mg/ml of AT inhibited the insulin effect by approximately 40% to 60% after incubation for 6 hours (■). AT had no such inhibitory effects over a shorter (30 min) incubation time.

*Example 4 – Concentration-dependent inhibitory effects of AT on insulin-stimulated glucose metabolism in differentiated L6 cells.*

Four groups of differentiated L6 cells, incubated in 12-well plates in 2% FBS-containing medium, were treated as follows. A first control group was untreated. A second group was treated with 500 nM insulin for 30 min. A third group was treated with 0.05 to 0.4 mg/ml of AT for 10 min. Finally, a fourth group was treated with 0.05 to 0.4 mg/ml of AT for 10 min followed by the addition of 500 nM insulin for 30 min. Following the addition of D-[<sup>14</sup>C]glucose, each group was then incubated in the continuous presence of insulin and AT for 5 hours.

For each group, the amounts of cellular radiolabeled glucose (Fig. 4A), glycogen (Fig. 4B), and total lipid (Fig. 4C) were determined by liquid scintillation counting. The data are the mean ± S.D. of three independent incubations in one experiment (the experiment was repeated once with similar results). In the absence of insulin ( ), the presence of AT did not significantly affect the cellular levels of any of these radiolabeled metabolites. However, in



the presence of insulin ( $\blacktriangle$ ), 0.2 to 0.4 mg/ml AT decreased the cellular levels of [ $^{14}$ C] glucose (Fig. 4A) as well as the synthesis of cellular [ $^{14}$ C] glycogen (Fig. 4B) and [ $^{14}$ C]total lipid (Fig. 4C) from [ $^{14}$ C] glucose by at least 50%.

5 *Example 5 – Gemfibrozil (GF) and lithocholic acid (LCA) prevent the inhibitory effect of AT on insulin-stimulated synthesis of glycogen in differentiated L6 cells.*

Three groups of differentiated L6 cells, incubated in 12-well plates in 2% FBS-containing medium were treated with insulin and AT as follows. A first control group was untreated. A second group was treated with 500 nM insulin for 30 min. A third group was treated with 0.4 mg/ml of AT for 10 min, followed by the addition of 500 nM insulin for 30  
10 min. Within each group were sub-groups where either no other compound was added ( $\square$ ), or 25 mM GF was added to the cells 60 min prior to AT ( $\square$ ), or 50  $\mu$ M LCA ( $\blacksquare$ ) was added to the cells 60 min prior to treatment with AT. Then, following the addition of D-[ $^{14}$ C]glucose, each group was incubated in the continuous presence of the above agents, as applicable, for 5 hours.

15 For each sub-group, the amount of cellular [ $^{14}$ C]glycogen was determined by liquid scintillation counting. The data are the mean  $\pm$  S.D. of four independent incubations in one experiment (the experiment was repeated once with similar results). As shown in Fig. 5, insulin stimulated the synthesis of [ $^{14}$ C]glycogen about two-fold, while the presence of AT inhibited the insulin effect by about 70%. In the presence of either GF or LCA, AT had no  
20 such inhibitory effect.

This invention may take on various modifications and alterations without departing from the spirit and scope thereof. Accordingly, it is to be understood that this invention is not to be limited to the above-described, but it is to be controlled by the limitations set forth in the following claims and any equivalents thereof. It is also to be understood that this  
25 invention may be suitably practiced in the absence of any element not specifically disclosed herein.

In describing preferred embodiments of the invention, specific terminology is used for the sake of clarity. The invention, however, is not intended to be limited to the specific terms

so selected, and it is to be understood that each term so selected includes all technical equivalents that operate similarly.

Alternative Embodiments of the Invention Include:

1. A method of treating or delaying the progression or onset of diabetes in a mammal comprising:
  - (a) identifying a mammal with an above-normal blood level of an inflammation marker protein; and
  - (b) administering to the mammal a therapeutically effective amount of an inhibitor of  $\alpha_1$ -antitrypsin.
2. The method of embodiment 1 where the step of identifying includes performing a radial immunodiffusion assay of a sample of the mammal's blood.
3. The method of embodiment 1 where the mammal is a human.
4. The method of embodiment 1 where the method is effective to maintain the human's blood glucose level below 10 mM.
5. The method of embodiment 1 where the method is effective to maintain the human's blood glucose level between 4 mM and 6 mM.
6. The method of embodiment 1 where the inflammation marker protein is  $\alpha_1$ -antitrypsin, C-reactive protein, interleukin-6 or a combination thereof.
7. The method of embodiment 6 where the above-normal blood level of  $\alpha_1$ -antitrypsin is greater than 1.3 mg  $\alpha_1$ -antitrypsin / mL blood.
8. The method of embodiment 1 where the inhibitor of  $\alpha_1$ -antitrypsin is gemfibrozil or an active derivative thereof.
9. The method of embodiment 8 where the therapeutically effective amount of gemfibrozil is between 300 and 1500 mg per day.
10. The method of embodiment 8 where the gemfibrozil is administered orally.

11. The method of embodiment 8 where the gemfibrozil is administered daily and the amount of gemfibrozil is adjusted daily to maintain a normal blood level of  $\alpha_1$ -antitrypsin.
12. The method of embodiment 8 where the gemfibrozil is administered once per day.
13. The method of embodiment 1 where the inhibitor of  $\alpha_1$ -antitrypsin is lithocholic acid or an active derivative thereof.
14. The method of embodiment 1 where the method further comprises the step of (c) co-administering to the mammal an anti-diabetic medicament.
15. The method of embodiment 14 where the anti-diabetic medicament includes insulin.
16. The method of embodiment 14 where the anti-diabetic medicament comprises an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or a combination thereof.
17. The method of embodiment 14 where the anti-diabetic medicament comprises human placental alkaline phosphatase.
18. The method of embodiment 1 where the method further comprises the step of (d) administering to the mammal an anti-inflammatory agent.
19. The method of embodiment 18 where the anti-inflammatory agent is a non-steroidal anti-inflammatory drug ("NSAID"), acetylsalicylic acid, ibuprofen, or an active derivative thereof.
20. The method of embodiment 18 where the anti-inflammatory agent is a cyclooxygenase-2 inhibitor.
21. A method of enhancing or restoring the sensitivity of a mammal to the metabolic actions of insulin comprising:

(a) identifying a mammal with an above-normal blood level of an inflammation marker protein; and

- (b) administering to the mammal an inhibitor of  $\alpha_1$ -antitrypsin sufficient to enhance or restore the sensitivity of the mammal to the metabolic actions of insulin.
22. The method of embodiment 21 where the step of identifying includes performing a radial immunodiffusion assay of a sample of the mammal's blood.
23. The method of embodiment 21 where the mammal is a human.
24. The method of embodiment 23 where the method is effective to maintain the human's blood glucose level below 10 mM.
25. The method of embodiment 23 where the method is effective to maintain the human's blood glucose level between 4 mM and 6 mM.
26. The method of embodiment 21 where the inflammation marker protein is  $\alpha_1$ -antitrypsin, C-reactive protein, interleukin-6 or a combination thereof.
27. The method of embodiment 26 where the above-normal blood level of  $\alpha_1$ -antitrypsin is greater than 1.3 mg  $\alpha_1$ -antitrypsin / mL blood.
28. The method of embodiment 21 where the inhibitor of  $\alpha_1$ -antitrypsin is gemfibrozil or an active derivative thereof.
29. The method of embodiment 28 where the therapeutically effective amount of gemfibrozil is between 300 and 1500 mg per day.
30. The method of embodiment 28 where the gemfibrozil is administered orally.
31. The method of embodiment 28 where gemfibrozil is administered daily and the amount of gemfibrozil is adjusted daily to maintain a normal blood level of  $\alpha_1$ -antitrypsin.
32. The method of embodiment 28 where the gemfibrozil is administered once per day.
33. The method of embodiment 21 where the inhibitor of  $\alpha_1$ -antitrypsin is lithocholic acid or an active derivative thereof.

34. The method of embodiment 21 where the method further comprises the step of (c) co-administering to the mammal an anti-diabetic medicament.
35. The method of embodiment 34 where the an anti-diabetic medicament includes insulin.
36. The method of embodiment 34 where the anti-diabetic medicament comprises an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or a combination thereof.
37. The method of embodiment 34 where the anti-diabetic medicament comprises human placental alkaline phosphatase.
38. The method of embodiment 21 where the method further comprises the step of (d) administering to the mammal an anti-inflammatory agent.
39. A method of enhancing or restoring the sensitivity of a diabetic human to the metabolic actions of insulin comprising:
- (a) identifying a diabetic human with an above-normal blood level of an inflammation marker protein; and
  - (b) administering to the diabetic human a therapeutically effective amount of an inhibitor of  $\alpha_1$ -antitrypsin sufficient to enhance or restore the sensitivity of the diabetic human to the metabolic actions of insulin.
40. The method of embodiment 39 where the step of identifying includes performing a radial immunodiffusion assay of a sample of the human's blood.
41. The method of embodiment 39 where the method is effective to maintain the human's blood glucose level below 10 mM.
42. The method of embodiment 39 where the method is effective to maintain the human's blood glucose level between 4 mM and 6 mM.

43. The method of embodiment 39 where the inflammation marker protein is  $\alpha_1$ -antitrypsin, C-reactive protein, interleukin-6 or a combination thereof.
44. The method of embodiment 43 where the above-normal blood level of  $\alpha_1$ -antitrypsin is greater than 1.3 mg  $\alpha_1$ -antitrypsin / mL blood.
45. The method of embodiment 39 where the inhibitor of  $\alpha_1$ -antitrypsin is gemfibrozil or an active derivative thereof.
46. The method of embodiment 45 where the therapeutically effective amount of gemfibrozil is between 300 and 1500 mg per day.
47. The method of embodiment 45 where the gemfibrozil is administered orally.
48. The method of embodiment 45 where the gemfibrozil is administered daily and the amount of gemfibrozil is adjusted daily to maintain a normal blood level of  $\alpha_1$ -antitrypsin.
49. The method of embodiment 45 where the gemfibrozil is administered once per day.
50. The method of embodiment 39 where the inhibitor of  $\alpha_1$ -antitrypsin is lithocholic acid or an active derivative thereof.
51. The method of embodiment 39 where the method further comprises the step of (c) co-administering to the human an anti-diabetic medicament.
52. The method of embodiment 51 where the anti-diabetic medicament includes insulin.
53. The method of embodiment 51 where the anti-diabetic medicament comprises an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or a combination thereof.
54. The method of embodiment 51 where the anti-diabetic medicament comprises human placental alkaline phosphatase.

55. The method of embodiment 39 where the method further comprises the step of (d) administering to the human an anti-inflammatory agent.
56. A treatment regimen for delaying the onset of diabetes in a mammal comprising:
- (a) identifying a mammal with an above-normal blood level of an inflammation marker protein; and
  - (b) periodically administering to the mammal an inhibitor of  $\alpha_1$ -antitrypsin.
57. The treatment regimen of embodiment 56 where the step of identifying includes performing a radial immunodiffusion assay of a sample of the mammal's blood.
58. The treatment regimen of embodiment 56 where the mammal is a human.
59. The treatment regimen of embodiment 58 where the method is effective to maintain the human's blood glucose level below 10 mM.
60. The treatment regimen of embodiment 58 where the method is effective to maintain the human's blood glucose level between 4 mM and 6 mM.
61. The treatment regimen of embodiment 56 where the inflammation marker protein is  $\alpha_1$ -antitrypsin, C-reactive protein, interleukin-6 or a combination thereof.
62. The treatment regimen of embodiment 61 where the above-normal blood level of  $\alpha_1$ -antitrypsin is greater than 1.3 mg  $\alpha_1$ -antitrypsin / mL blood.
63. The treatment regimen of embodiment 56 where the inhibitor of  $\alpha_1$ -antitrypsin is gemfibrozil or an active derivative thereof.
64. The treatment regimen of embodiment 63 where the amount of gemfibrozil is between 300 and 1500 mg per day.
65. The treatment regimen of embodiment 63 where the gemfibrozil is administered orally.



66. The treatment regimen of embodiment 63 where the gemfibrozil is administered daily and the amount of gemfibrozil is adjusted daily to maintain a normal blood level of  $\alpha_1$ -antitrypsin.
67. The treatment regimen of embodiment 63 where the gemfibrozil is administered once per day.
68. The treatment regimen of embodiment 56 where the inhibitor of  $\alpha_1$ -antitrypsin is lithocholic acid or an active derivative thereof.
69. The treatment regimen of embodiment 56 where the treatment regimen further comprises the step of (c) co-administering to the mammal an anti-diabetic medicament.
70. The treatment regimen of embodiment 69 where the anti-diabetic medicament includes administering insulin.
71. The treatment regimen of embodiment 69 where the anti-diabetic medicament comprises administering an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or a combination thereof.
72. The treatment regimen of embodiment 69 where the anti-diabetic medicament comprises human placental alkaline phosphatase.
73. The treatment regimen of embodiment 56 where the treatment regimen further comprises the step of (d) administering to the mammal an anti-inflammatory agent.
74. A treatment regimen for treating the progression of diabetes in a mammal comprising:
- (a) identifying a diabetic mammal with an above-normal blood level of an inflammation marker protein; and
  - (b) administering to the mammal a therapeutically effective amount of an inhibitor of  $\alpha_1$ -antitrypsin as needed.


75. The treatment regimen of embodiment 74 the step of identifying includes performing a radial immunodiffusion assay of a sample of the mammal's blood.
76. The treatment regimen of embodiment 74 where the mammal is a human.
77. The treatment regimen of embodiment 76 where the method is effective to maintain the human's blood glucose level below 10 mM.
78. The treatment regimen of embodiment 76 where the method is effective to maintain the human's blood glucose level between 4 mM and 6 mM.
79. The treatment regimen of embodiment 74 where the inflammation marker protein is  $\alpha_1$ -antitrypsin, C-reactive protein, interleukin-6 or a combination thereof.
80. The treatment regimen of embodiment 79 where the above-normal blood level of  $\alpha_1$ -antitrypsin is greater than 1.3 mg  $\alpha_1$ -antitrypsin / mL blood.
81. The treatment regimen of embodiment 74 where the inhibitor of  $\alpha_1$ -antitrypsin is gemfibrozil or an active derivative thereof.
82. The treatment regimen of embodiment 81 where the therapeutically effective amount of gemfibrozil is between 300 and 1500 mg per day.
83. The treatment regimen of embodiment 81 where the gemfibrozil is administered orally.
84. The treatment regimen of embodiment 81 where the gemfibrozil is administered daily and the amount of gemfibrozil is adjusted daily to maintain a normal blood level of  $\alpha_1$ -antitrypsin.
85. The treatment regimen of embodiment 81 where the gemfibrozil is administered once per day.
86. The treatment regimen of embodiment 74 where the inhibitor of  $\alpha_1$ -antitrypsin is lithocholic acid or an active derivative thereof.

87. The treatment regimen of embodiment 74 where the treatment regimen further comprises the step of (c) co-administering to the mammal an anti-diabetic medicament.
88. The treatment regimen of embodiment 87 where the anti-diabetic medicament includes insulin.
89. The treatment regimen of embodiment 87 where the anti-diabetic medicament comprises an insulin secretagogue, a biguanide, an inhibitor of  $\alpha$ -glucosidase, a thiazolidinedione, or a combination thereof.
90. The treatment regimen of embodiment 87 where the anti-diabetic medicament comprises human placental alkaline phosphatase.
91. The treatment regimen of embodiment 74 where the method further comprises the step of (d) administering to the mammal an anti-inflammatory agent.
92. The treatment regimen of embodiment 74 where the treatment regimen further comprises the step of (e) monitoring the level of AT in the mammal's blood.

M2:20584226.02


FIGURE 1

BEST AVAILABLE COPY




BEST AVAILABLE COPY


FIGURE 2



BEST AVAILABLE COPY


FIGURE 3





**FIGURE 4**

FIGURE 5



BEST AVAILABLE COPY